Abstract-Pathological cardiac hypertrophy is a key risk factor for heart failure. We found that the protein expression levels of the ZNF307 (zinc finger protein 307) were significantly increased in heart samples from both human patients with dilated cardiomyopathy and mice subjected to aortic banding. Therefore, we aimed to elucidate the role of ZNF307 in the development of cardiac hypertrophy and to explore the signal transduction events that mediate the effect of ZNF307 on cardiac hypertrophy, using cardiac-specific ZNF307 transgenic (ZNF307-TG) mice and ZNF307 global knockout (ZNF307-KO) mice. The results showed that the deletion of ZNF307 potentiated aortic banding-induced pathological cardiac hypertrophy, fibrosis, and cardiac dysfunction; however, the aortic bandinginduced cardiac hypertrophic phenotype was dramatically diminished by ZNF307 overexpression in mouse heart. Mechanistically, the antihypertrophic effects mediated by ZNF307 in response to pathological stimuli were associated with the direct inactivation of NF-κB (nuclear factor-κB) signaling and blockade of the nuclear translocation of NF-κB subunit p65. Furthermore, the overexpression of a degradation-resistant mutant of IκBα (IκBα S32A/S36A ) reversed the exacerbation of cardiac hypertrophy, fibrosis, and dysfunction shown in aortic banding-treated ZNF307-KO mice.
H ypertrophy of the myocardium initially serves to preserve the pumping function of the heart and reduces ventricular wall stress; however, persistent cardiac hypertrophy induced by pathological conditions, such as hypertension, may eventually lead to ventricular dilation, heart failure, or sudden death. 1 Aberrant hypertrophic growth is triggered by different stimulus signals occurring at the cell membrane, which are then sequentially transferred by various complex networks of intracellular signal transduction pathways in the heart cells, for example, MAPK (mitogen-activated protein kinase), Ca 2+ -calcineurin-NFAT (nuclear factor of activated T cells), and PI3K-Akt (phosphatidylinositol 3 kinase-protein kinase B) signaling. [2] [3] [4] [5] These signal transduction pathways ultimately result in the activation or inhibition of transcription factors that modulate the expression of genes related to hypertrophic growth. Transcription factors, such as NF-κB (nuclear factor-κB), 6 NFAT, 7 MEF2, 8 and GATA4/6, 9,10 are directly activated by cytoplasmic signaling effectors and facilitate hypertrophic gene expression. Although numerous studies have been performed to decipher the regulatory mechanisms underlying the development of cardiac hypertrophy, these mechanisms have remained unclear.
Zinc finger proteins (ZFPs) represent the most abundant class of proteins in the human proteome. Based on the multifunctional basic element zinc finger domain, ZFPs play important roles in cell growth, differentiation, development, and disease. 11, 12 The Cys2His2 (C2H2)-ZFP accounts for the highest proportion of ZFPs; among these, ZNF307 (zinc finger protein 307) is evolutionarily conserved across species and is widely expressed in adult human heart, brain, lung, and kidney. 13 Studies on the structural characteristics of ZNF307 have indicated that it bears a SCAN (SRE-ZBP, CTfin51, AW-1 [ZNF174], and Number 18 cDNA) domain, a leader region before SCAN domain, and a KRAB (Krüppel-associated box) domain at the N terminus, whereas the C terminus harbors 7 C2H2-zinc finger motifs. Data from functional studies on differentially truncated ZNF307 proteins suggest that ZNF307 exerts suppressive effects on a variety of factors, including SRF (serum response factor), AP-1 (activator protein-1), NF-κB, p53 (protein 53), and p21 (protein 21) mainly through the leader region before SCAN domain and the KRAB domain. 13 Importantly, SRF, AP-1, and NF-κB play important roles in developing cardiac hypertrophy. 6, 14, 15 On the basis of the facts that ZNF307 is expressed in heart and its downstream molecular events, such as NF-κB, hold potential regulatory capacity in cardiac remodeling, we hypothesized that ZNF307 may play a critical role in the regulation of pressure overload-induced cardiac hypertrophy.
Here, we present evidence that ZNF307 expression is drastically upregulated in heart samples from both human patients with dilated cardiomyopathy (DCM) and pressure overload-induced cardiac hypertrophic mouse model. Further experiments demonstrated that ZNF307 exerts an antihypertrophic effect both in vivo and in vitro, via inhibiting NF-κB-signaling activity.
Methods
A detailed Methods section is available in the online-only Data Supplement.
Experimental Mouse Models
All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of both Harbin Medical University Cancer Hospital and Renmin Hospital of Wuhan University and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Generation of ZNF307 Knockout Mice
We predicted and constructed the guide sequences that target the ZNF307 gene in the mouse genome using the online CRISPR design tool (http://crispr.mit.edu; Figure S2A in the online-only Data Supplement). The paired synthesized oligonucleotides (oligo 1: TAGGGGCTCAGCGCCTGCCGGGGTC and oligo 2: AAACGACCCCGGCAGGCGCTGAGCC) were annealed and cloned into the pUC57-sgRNA expression vector (Addgene 51132). Specific primers (forward primer: GATCCCTAATACGACTCACTATAG; reverse primer: AAAAAAAGCACCGACTCGGT) spanning the T7 promoter and sgRNA regions were used to amplify the DNA by using polymerase chain reaction. After DNA purification, the sgRNA was transcribed using a MEGA shortscript Kit (Ambion; AM1354) and purified with a miRNeasy Micro Kit (QIAGEN; 217084). A Cas9 expression plasmid (Addgene 44758) was linearized and served as the template for in vitro transcription using the T7 Ultra Kit (Ambion, AM1345). Purification of mRNA was used by RNeasy Mini Kit (QIAGEN, 74104) according to the manufacturer's instructions. Both the transcribed Cas9 mRNA and sgRNA were injected into a (one-cell embryo) fertilized mouse egg using a FemtoJet 5247 microinjection system under standard conditions. Genomic DNA obtained from a mouse tail biopsy was extracted and used for founder identification. Primers flanking the sgRNA target site (forward: 5′-GCTAGAGAACCCGGAACGTC-3′; reverse: 5′-GCTGCCTGTCCAAGTACTCC-3′) were used to amplify a wild-type (WT) amplicon of 397 bp. Heteroduplex DNA was formed through the denaturation and reannealing of the purified polymerase chain reaction products, followed by digestion with T7EN (NEB, M0302L) and analysis with agarose gel electrophoresis ( Figure S2B ). Genetic-sequencing technology was applied to identify the missing base number and location on the engineered gene ( Figure S2C) ; then, the proper founder was used to produce offspring. Finally, the F1 and F2 offspring were further analyzed via genetic-sequencing technology ( Figure S2D ).
Generation of ZNF307 Transgenic Mice
We initially generated transgenic (TG) mice carrying a construct of the CAG gene promoter-loxP-CAT gene-loxP-mZNF307 region (designated CAG-CAT-mZNF307 TG mice). Founder TG mice were identified by tail DNA amplification and then bred with C57BL/6J mice. The polymerase chain reaction primers used for TG detection were CAG-forward (5′-CCCCCTGAACCTGAAACATA-3′) and ZNF307-reverse (5′-AGGCCTCTTCCTGTTCCACT-3′), which yielded a 463-bp product. When the CAG-CAT-mZNF307-TG mice were crossed with α-MHC-MerCreMer-TG mice (Myh6-cre/Esr1; Jackson Laboratory; 005650), the tamoxifen-inducible Cre-mediated recombination was expected to result in the deletion of CAT gene, leading to the expression of mZNF307 specifically in the myocardium of the offspring. The CAG-CAT-mZNF307/α-MHC-MerCreMer mice at 6 weeks of age were injected IP with tamoxifen at 20 μg/g body weight/d for 5 consecutive days to generate cardiac-specific ZNF307-overexpressed mice. Mice with tamoxifen treatment and successful ZNF307 overexpression were designated as ZNF307-TG mice, whereas mice that did not receive tamoxifen administration (hereafter referred to as CZMC mice) served as control. -TG mice, which were then crossed back with ZNF307-KO mice to obtain ZNF307-KO/IκBα S32A/S36A -TG mice.
Generation of ZNF307

Human Heart Samples
All the procedures involving human samples were approved by the Renmin Hospital of Wuhan University Review Board and conformed to the principles outlined in the Declaration of Helsinki. Left ventricle samples of failing human heart were collected from dilated cardiomyopathy (DCM) patients. Left ventricle samples of control human heart were obtained from healthy donors who died in accidents, and whose hearts were unsuitable for transplantation because of noncardiac reasons. Written informed consent was obtained from the patients and families of the donors. Detailed information on the human heart samples is provided in Table S1 .
Statistical Analysis
The data are expressed as the mean±SD. All statistical analyses were performed with SPSS software, version 20.0 (SPSS, Chicago, IL). Comparison between 2 groups was performed using Student t test. Differences among groups were calculated for significance by using 1-way ANOVA with Bonferroni test (equal variances assumed) or Tamhane's T2 test (equal variances not assumed). Two-way ANOVA test was performed to compare significant between 2 distinct independent variables. A value of P<0.05 was considered statistically significant.
Results
ZNF307 Expression Is Upregulated in Human DCM Heart Specimens and Mouse Hypertrophic Hearts
To define the role of ZNF307 in cardiac hypertrophy, we first detected the expression changes of ZNF307 during cardiac hypertrophy. We found that ZNF307 expression was significantly upregulated in the left ventricle tissues of human hearts with DCM compared with that of human hearts from normal donors (controls), in parallel with increased levels of the hypertrophic indices including ANP (atrial natriuretic peptide) and β-MHC (β-myosin heavy chain; Figure 1A ; refer to the onlineonly Data Supplement file for details). To explore the potential role of ZNF307 in developing cardiac hypertrophy, an experimental mouse model of aortic banding (AB)-induced cardiac hypertrophy was used. The data showed that in addition to the elevated protein expression levels of ANP and β-MHC, ZNF307 levels were also significantly upregulated in mouse left ventricle tissues 4 or 8 weeks after AB compared with the sham-operated controls ( Figure 1B) . Furthermore, higher levels of ZNF307, ANP, and β-MHC were also detected in angiotensin II (Ang II; 1 μmol/L)-treated primary cultured neonatal rat cardiomyocytes (NRCMs; Figure 1C) . Surprisingly, there were no significant increases in ZNF307 gene expression in human and mouse hypertrophic specimens, as well as in Ang II-stimulated NRCMs (Figure S1A through S1C). These data suggest that ZNF307 may be involved in the development of pathological cardiac hypertrophy.
ZNF307-KO Mice Are More Susceptible to Pressure Overload-Induced Cardiac Hypertrophy
To examine whether endogenous ZNF307 contributes to cardiac hypertrophy, we generated global ZNF307-KO mice ( Figure S2A through S2D). The absence of ZNF307 in the mouse hearts was confirmed by Western blot ( Figure S2E ). These mice did not display any apparent differences in heart morphology or function at baseline compared with age-and sex-matched mouse hearts (data not shown). As expected, hypertrophic phenotype was observed in WT mice 4 weeks after AB, which was indicated by significant increases in the ratios of heart weight (HW) to tibia length (Figure 2A ), HW to body weight (HW/BW; Figure S3A ), and lung weight to BW ( Figure S3B ). Notably, these hypertrophic indices were further increased in ZNF307-KO mice (Figure 2A ; Figure  S3A and S3B). The hypertrophic phenotype was not seen in sham-operated WT or ZNF307-KO mice; however, it seemed that AB resulted in more severe hypertrophic phenotype in ZNF307-KO mice than in WT mice, as visualized by hematoxylin and eosin and wheat germ agglutinin (WGA) staining ( Figure 2B) . Consistently, the mRNA expression levels of ANP, brain natriuretic peptide (BNP), β-MHC, and skeletal α-actin (ACTα1) were further enhanced by AB operation in ZNF307-KO mice compared with AB-treated WT mice ( Figure 2E ). AB-induced decrease in cardiac calcium Picrosirius red staining demonstrated that AB-induced perivascular and interstitial fibrosis in hearts of WT mice were more severe in that of the ZNF307-KO mice ( Figure 2D ). Consistently, mRNA levels of several fibrotic markers, including collagen I, collagen III, and CTGF (connective tissue growth factor) were significantly enhanced in ZNF307-KO mice compared with WT mice ( Figure 2E ). Hence, these data demonstrate that ZNF307 deficiency sensitizes mice to hypertrophic stimuli and that ZNF307 may be a negative regulator in developing pathological cardiac hypertrophy.
ZNF307 Overexpression Suppresses Pressure Overload-Induced Cardiac Hypertrophy
TG mice, capable of inducible cardiac-specific ZNF307 overexpression, were generated ( Figure S3E ) and used to determine whether the overexpression of ZNF307 could attenuate AB-induced hypertrophy. Cardiac-specific overexpression was determined by Western blots ( Figure S3F ). Among the 4 independent lines of ZNF307-TG mice, line 4 had highest ZNF307 expression levels (≈3.7-fold higher than their CZMC littermates; Figure S3G ). Therefore, line 4 ZNF307-TG mice and their CZMC littermates were used for further experiments. Four weeks after sham operation, no comparable differences in HW to tibia length, HW/BW, and lung weight to BW were observed between the CZMC and ZNF307-TG mice; however, the AB-induced increase in these indices in WT mice was greatly attenuated by ZNF307-TG overexpression ( Figure 3A ; Figure S3H and S3I). Compared with CZMC mice, AB-induced cardiac hypertrophy and enlargement of cardiomyocytes were greatly decreased by ZNF307 overexpression ( Figure 3B ). AB-induced impairment in cardiac function of CZMC mice was significantly alleviated in ZNF307-TG mice at the indicated time ( Figure 3C ; Figure  S3J and S3K). Furthermore, AB-induced increase in ANP, BNP, β-MHC, and ACTα1 levels, in the left ventricle tissues isolated from CZMC mice, were also dramatically blunted by ZNF307 overexpression; whereas, AB-induced decrease in SERCA2a, PPARα, PGC-1α, and PDK-4 levels were significantly rescued by ZNF307 overexpression ( Figure 3E ). The collagen volume ( Figure 3D ) and expression levels of collagen I, collagen III, and CTGF ( Figure 3E ) were also significantly decreased by ZNF307 overexpression. Collectively, these results suggest that ZNF307 overexpression could attenuate the maladaptive cardiac remodeling in response to pressure overload. 
ZNF307 Attenuates Ang II-Induced Cardiomyocyte Hypertrophy In Vitro
We next generated a recombinant adenoviral vector expressing short hairpin RNA against ZNF307 (AdshZNF307) or full-length ZNF307 cDNA (AdZNF307) to knockdown or overexpress ZNF307 in NRCMs. Western blot analyses showed that expression levels of ZNF307 were effectively knocked down by AdshZNF307 or upregulated by AdZNF307 ( Figure S4A ). Compared with PBS-stimulated cells, application of Ang II (1 μmol/L) to NRCMs resulted in a significant increase in the mean cross-sectional area of AdshRNA-or AdGFP-infected NRCMs, which was further enhanced by knocking down of ZNF307 (AdshZNF307) or was greatly reduced by overexpression of ZNF307 (AdZNF307; Figure  S4B through S4D). Furthermore, Ang II-induced elevation of ANP, BNP, and β-MHC mRNA expression levels were greatly enhanced by knocking down of ZNF307 in NRCMs ( Figure  S4E ), whereas Ang II-induced increases of these hypertrophic markers were dramatically decreased by overexpression of ZNF307 ( Figure S4F ). These data further confirmed the antihypertrophic effect of ZNF307 in cardiomyocyte subjected to hypertrophic stresses. 
Inhibitory Effect of ZNF307 on NF-κB Signaling
To explore the mechanisms by which ZNF307 acts as negative regulator in cardiac hypertrophy, we performed a dualluciferase reporter analysis. The results showed that relative to the GFP control, the activities of a large number of signaling pathways were either upregulated or downregulated on application of Ang II (1 μmol/L) to a heart-derived cell line, H9c2 cells overexpressing ZNF307; among which, the activity of NF-κB was dramatically blunted by ZNF307 overexpression ( Figure S5A ). NF-κB signaling plays a critical role in developing pathological cardiac hypertrophy. 16, 17 Therefore, we examined whether activities of NF-κB-signaling pathway members, that is, IKKβ, IκBα, and p65, could be associated with gain or loss of function of ZNF307. The phosphorylated levels of IKKβ (P-IKKβ), IκBα (P-IκBα), and p65 (P-p65) were significantly increased in the left ventricle tissues of AB-treated ZNF307-KO mice ( Figure 4A ) and decreased in that of AB-treated ZNF307-TG mice ( Figure 4B ) compared with their respective control groups. Consistently, application of Ang II resulted in significant increases in P-IKKβ, P-IκBα, and P-p65 levels in ZNF307-knockdown NRCMs, whereas overexpressing ZNF307 in NRCMs greatly decreased the phosphorylated levels of these NF-κB members ( Figure S5B and S5C).
NF-κB activity is dependent on the phosphorylated activation and nuclear translocation of p65. 18 Our data showed that AB-induced nuclear entry of P-p65 in the left ventricular tissues was significantly enhanced by ZNF307 deletion ( Figure 4C ), which was greatly attenuated by ZNF307 overexpression ( Figure 4D) . Similarly, Ang II-induced increase in nuclear entry of P-p65 was greatly enhanced by ZNF307 knockdown (Figure S5D ) or significantly reduced by overexpression of ZNF307 in NRCMs ( Figure S5E ). We next performed coimmunoprecipitation to detect the possible mechanism that there might be a physical interaction between ZNF307 and NF-κB, using HEK293T cells cotransfected with Flag-tagged ZNF307 and HA-tagged IKKβ. These results suggest that ZNF307 interacts with IKKβ ( Figure 5A and 5B). More importantly, coimmunoprecipitation data demonstrated that ZNF307 constitutively interacts with IKKβ in NRCMs and that the magnitude of this interaction was greatly enhanced by Ang II stimulation ( Figure 5C ).
Inhibition of NF-κB Suppresses AB-Induced Cardiac Hypertrophy
To further test the hypothesis that the NF-κB activation plays an essential role in mediating stress-induced cardiac hypertrophy in ZNF307-KO mice, a rescue experiment was conducted. A mutant IκBα, the nondegradable IκBα S32A/S36A
, was cardiac specifically introduced into the ZNF307-KO mice by crossing them with the IκBα S32A/S36A -TG mice. The cardiac-specific overexpression of IκBα S32A/S36A and the absence of ZNF307 were, respectively, validated by Western blots (Figure S6A and S6B). Consistently, AB-induced increases in the ratios of HW to tibia length ( Figure 6A ), the mean cross-sectional area ( Figure 6B and 6C) , HW/BW ( Figure S6C ), and lung weight to BW ( Figure S6D ) seen in nontransgenic mice were further increased in ZNF307-KO mice; however, cardiac-specific overexpression of IκBα S32A/S36A diminished AB-induced hypertrophic phenotypes, even in ZNF307-KO mice (Figure 6A through 6C; Figure S6C and S6D) . Moreover, the aggravated effects of ZNF307-KO on AB-induced cardiac dysfunction and fibrosis were also significantly improved by the overexpression of IκBα S32A/S36A ( Figure 6B , 6D, and 6E; Figure S6E and S6F).
Discussion
The major findings of the present study are (1) the expression of ZNF307 was significantly elevated in human cardiac hypertrophic samples and increased in the mouse left ventricular tissues in response to hypertrophic stimuli; (2) ZNF307 deficiency in mice exacerbated AB-induced cardiac hypertrophy, fibrosis, and dysfunction. Antithetically, AB-produced hypertrophic phenotypes were significantly improved by cardiacspecific ZNF307 overexpression; and (3) ZNF307 exerts a protective effect on stress-induced cardiac hypertrophy, most likely through a direct binding with IKKβ to inhibit nuclear entry of P-p65.
C2H2-ZFP, as the largest class of putative human transcription factors, plays important roles in various human diseases, including heart dysfunction. [19] [20] [21] However, the role of ZNF307, a member of C2H2-ZFP, in the development of cardiac hypertrophy remains unknown. On the basis of the findings that protein expression levels of ZNF307 in human cardiac hypertrophic samples were significantly upregulated, we used gain-and loss-of-function mouse models to study the potential role and underlying mechanisms of ZNF307 in stress-induced hypertrophy. Our data show that mice underwent AB for 4 weeks or NRCMs stimulated with Ang II over 48 hours resulted in hypertrophic phenotypes, in parallel with an enhanced protein expression of ZNF307, suggesting potential involvement of ZNF307 in developing cardiac hypertrophy. Interestingly and surprisingly, AB-induced cardiac hypertrophy, fibrosis, cardiac dysfunction, and cardiac energy metabolic disorder were aggravated in ZNF307-KO mice, whereas AB-induced cardiac injury was greatly attenuated in ZNF307-TG mice. These results strongly suggest that ZNF307 exerts a protective effect against stress-induced cardiac hypertrophy and that increased protein expression of ZNF307 seen in hypertrophic samples might be a compensative reaction to prohypertrophic stimuli. However, the mRNA levels of ZNF307 were not altered in human and mouse hypertrophic samples and in Ang II-stimulated NRCMs compared with their respective controls. The similar expression patterns were seen in other negative regulators (eg, IRF9 and Trx1) of cardiac hypertrophy. 22, 23 This phenomenon may arise from the decreased degradation of protein under stress stimulation or other unknown mechanisms. It should be noted that as seen in other gene KO animal models, 24, 25 ZNF307-KO does not produce spontaneous cardiac hypertrophy, which could be attributed to a compensative effect of other molecular regulators, in the complex organisms of the heart, on the loss of ZNF307 function in ZNF307-KO mice. Nevertheless, we suggest that ZNF307 acts as an endogenous cardioprotective regulator against stress.
To explore the potential mechanisms by which ZNF307 exerts a protective effect on stress-induced hypertrophy, the Representative Western blots demonstrating the phosphorylated and total protein levels of IKKβ, IκBα, and p65 in the left ventricle tissues of wild-type (WT) and ZNF307 global knockout (ZNF307-KO) mice at 4 wk after sham or AB operation. Right: Quantified results of P-IKKβ, P-IκBα, T-IκBα, and P-p65 in the indicated groups (n=6 mice/group). B, Left: Representative Western blots demonstrating the phosphorylated and total protein levels of IKKβ, IκBα, and p65 in the left ventricular tissues of CZMC and ZNF307 transgenic (ZNF307-TG) mice at 4 wk after sham or AB operation. Right: Quantified expression levels of P-IKKβ, P-IκBα, T-IκBα, and P-p65 in the indicated groups (n=6 mice/group). C and D, Representative Western blots (left) and quantitative results (right), respectively, showing P-p65 levels in the cytoplasm; P-p65 and T-p65 levels in the nuclei of ZNF307-KO mice (C) or ZNF307-TG mice (D), at 4 wk after sham or AB operation (n=4 mice/group). *P<0.05, compared between different treatments for mice of the same genotype; and #P<0.05, compared between different genotypes of mice with the same treatment.
activities of a variety of signaling pathways were examined in H9c2 cells overexpressing ZNF307. Among 45 molecules measured, the activation of NF-κB was extremely downregulated by Ang II. The data obtained from both in vivo and in vitro experiments pointed out that the stresses-induced increases of phosphorylated levels of NF-κB-signaling members were dramatically enhanced by ZNF307-KO in mice or in ZNF307 knocking down NRCMs; conversely, upregulated activity of NF-κB signaling by AB or Ang II was greatly attenuated by overexpression of ZNF307. As the upstream kinase, the activated IKKβ initiates the phosphorylation and degradation of IκBα and the following release of NF-κB. 17, 18 Our data showed that there is a direct interaction between ZNF307 and IKKβ and that this association was greatly enhanced by prohypertrophic stimulus in NRCMs. Additionally, stress-induced increases in P-p65 levels and in p65 nuclear entry were significantly enhanced by ZNF307 deficiency both in vivo and in vitro, whereas overexpression of ZNF307 significantly attenuated stress-induced activation and nuclear entry of p65. Therefore, we suggest that ZNF307 could directly bind with IKKβ and inhibit the activation of the NF-κB signaling by blockade of the nuclear translocation of p65.
For NF-κB activation, IκBα is required to be degraded after phosphorylation by IKKβ. 26 Thus, it is pivotal for us to further illustrate whether IκBα serves as an essential link between ZNF307 and ZNF307-regulated NF-κB signaling during cardiac hypertrophy. We found that the artificial overexpression of a phosphorylation-resistant IκBα mutant, IκBα S32A/S36A
, in mice dramatically attenuated AB-triggered cardiac hypertrophy, which was consistent with the previous finings using different types of IκBα mutant. 17, [27] [28] [29] Of note, in the subsequent rescue experiment, the deteriorative effect of ZNF307 deficiency on AB-induced cardiac hypertrophy, fibrosis, and dysfunction was almost abolished by IκBα S32A/S36A overexpression. These results together suggest that IκBα plays a crucial role in ZNF307-regulated NF-κB signaling. Therefore, the effects of ZNF307 deficiency on AB-induced cardiac hypertrophy could be overridden by overexpression of IκBα S32A/S36A . Moreover, IκBα S32A/S36A overexpression in ZNF307-KO mice could predispose the mouse hearts on its own, thereby separating from ZNF307 deficiency to the AB-induced cardiac impairment. Nevertheless, these results are consistent with the notion that the antihypertrophic effect of ZNF307 is largely dependent on inhibition of NF-κB signaling.
In conclusion, we demonstrate that ZNF307 significantly blunts pathological cardiac hypertrophy, fibrosis, and dysfunction, at least in part, by inhibiting the IKKβ-IκBα-NF-κB-signaling pathway. These findings suggest ZNF307 may be a potential therapeutic target for prevention and treatment of cardiac hypertrophy and heart failure.
Perspectives
The present study provides evidence that ZNF307 negatively regulates pressure overload-induced cardiac hypertrophy through inhibition of the NF-κB signaling by limiting nuclear entry of p65, which may arise from a direct association between ZNF307 and IKKβ. Our findings amplify the spectrum of endogenous antihypertrophic molecules. Our results suggest that pharmacological or biological approaches to increase ZNF307 expression may provide a promising therapeutic strategy for the treatment of cardiac hypertrophy.
